SEC Form 4 · accession 0001209191-16-089844
Regulus Therapeutics Inc. · RGLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph P Hagan
Officer — Chief Operating Officer
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $8.57 | Jan 4, 2016 | A | 420,000 | A | — | Jan 3, 2026 | Common Stock | 420,000 | 420,000 | D |
Explanation of responses
- F125% of the shares vested on January 4, 2017 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on January 4, 2020.